Gonadotrophin-releasing hormone antagonists: Will they replace the agonists?

Reproductive BioMedicine Online

Volumn 6, Issue 1, 2003, Pages 43-53

  Felberbaum, Ricardo E ^a   Diedrich, Klaus ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

Author keywords

Friendly IVF; GnRH antagonists; OHSS; Pregnancy rates

Indexed keywords

BUSERELIN; CETRORELIX; CLOMIFENE CITRATE; ESTRADIOL; GANIRELIX; GONADORELIN; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; GONADOTROPIN; GONADOTROPIN ANTAGONIST; GOSERELIN; HUMAN MENOPAUSAL GONADOTROPIN; ITURELIX; LEUPRORELIN; LUTEINIZING HORMONE; ORAL CONTRACEPTIVE AGENT; PROGESTERONE; TRIPTORELIN;

ALLERGIC REACTION; ARTICLE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; EDEMA; FEMALE; FERTILIZATION; FIRST TRIMESTER PREGNANCY; HEALTH STATUS; HORMONAL REGULATION; HORMONE INHIBITION; HUMAN; HYPERSENSITIVITY; HYPOPHYSIS FUNCTION; LUTEINIZING HORMONE RELEASE; MENSTRUAL CYCLE; MULTIPLE DRUG DOSE; OVARY CYST; OVARY HYPERSTIMULATION; OVARY INSUFFICIENCY; PAIN; PATIENT COMPLIANCE; PREGNANCY RATE; PREGNANCY TEST; PROGENY; PROSPECTIVE STUDY; PRURITUS; RISK ASSESSMENT; SECOND TRIMESTER PREGNANCY; SINGLE DRUG DOSE; SKIN BRUISING; THIRD TRIMESTER PREGNANCY; WITHDRAWAL SYNDROME; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; LUTEAL PHASE; METABOLISM; OVARY; PREGNANCY;

FEMALE; GONADOTROPIN-RELEASING HORMONE; GONADOTROPINS; HUMANS; LUTEAL PHASE; OVARIAN CYSTS; OVARIAN HYPERSTIMULATION SYNDROME; OVARY; PREGNANCY;

EID: 0038265887     PISSN: 14726483     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1472-6483(10)62054-8     Document Type: Article

References (63)

1. Abdallah HI, Aguja KK, Leonard T et al. 1990 Comparative trial of luteinizing hormone releasing hormone analog/human menopausal gonadotropin and clomiphene citrate/human menopausal gonadotropin in an assisted conception program. Fertility and Sterility 53, 473-478.
2. Akman MA, Erden HF, Tosun SB et al. 2000 Addition of GnRH antagonist in cycles of poor responders undergoing IVF. Human Reproduction 15, 2145-2147.
3. Albano C, Smitz J, Camus M et al. 1997 Comparison of different doses of gonadotropin-releasing hormone antagonist cetrorelix during controlled ovarian hyperstimulation. Fertility and Sterility 67, 917-922.
4. Albano C, Grimbizis G, Smitz J et al. 1998 The luteal phase of nonsupplemented cycles after ovarian superovulation with human menopausal gonadotropin and the gonadotropin-releasing hormone antagonist cetrorelix. Fertility and Sterility 70, 357-359.
5. Albano C, Felberbaum RE, Smitz J et al. 2000 Controlled ovarian stimulation with HMG: results of a prospective randomized phase III European study comparing the GNRH-antagonist cetrorelix (Cetrotide) and the GNRH-agonist Buserelin. Human Reproduction 15, 526-531.
6. Al-Inany, Aboulghar M 2002 GnRH antagonist in assisted reproduction: a Cochrane review. Human Reproduction 17, 874-885.
7. Balasch J, Barri PN 2001 Reflections on the cost effectiveness of recombinant FSH in assisted reproduction. The clinician's perspective. Journal of Assisted Reproduction and Genetics 18, 45-55.
8. Bauer O, Diedrich K 1996 Komplikationen der assistierten Reproduktion Gynäkologe 29, 464-473.
9. Chillik C, Acosta A 2001 The role of LHRH agonists and antagonists. Reproductive BioMedicine Online 2, 120-128.
10. Daya S 1997 Optimal protocol for gonadotropin relesasing hormone agonist use in ovarian stimulation. Abstract book 10th World Congress on In Vitro Fertilization and Assisted Reproduction, Vancouver, Canada, 24-28 May, 1995, pp. 405-10.
11. Daya S, Ledger W, Away JS et al. 2001 Cost-effectiveness modelling of recombinant FSH versus urinary FSH in assisted reproduction techniques in the UK. Human Reproduction 16, 2563-2569.
12. De Jong D, Macklon NS, Fauser BC 2000 A pilot study involving minimal ovarian stimulation for in vitro fertilization: extending the 'follicle-stimulating hormone window' combined with the gonadotropin-releasing hormone antagonist cetrorelix. Fertility and Sterility 73, 1051-1054.
13. Deutsches IVF-Register-Jahrbuch 2000. Deutsches IVF-Register, Bundesgeschäftsstelle Ärztekammer Schleswig-Holstein, Bismarckallee 8-12; 23795 Bad Segeberg, Germany.
14. Diedrich K, Diedrich C, Santos E et al. 1994 Suppression of the endogenous luteinizing hormone surge by the gonadotrophin-releasing hormone antagonist cetrorelix during ovarian stimulation. Human Reproduction 9, 788-791.
15. Diedrich K, Ludwig M, Felberbaum R 2001 The role of gonadotropin-releasing hormone antagonists in in vitro fertilization. Seminars in Reproductive Medicine 19, 213-220.
16. Dittkoff EC, Cassidenti DL, Paulson RJ et al. 1991 The gonadorophin releasing hormone antagonist (Nal-Glu) acutely blocks the luteinizing hormone surge but allows for resumption of folliculogenesis in normal women. American Journal of Obstetrics and Gynecology 165, 1811-1817.
17. Edwards RG, Lobo R, Bouchard P 1996 Time to revolutionize ovarian stimulation. Human Reproduction 11, 917-920.
18. Elchalal U, Schenker JG 1997 The pathophysiology of ovarian hyperstimulation syndrome - views and ideas. Human Reproduction 12, 1129-1137.
19. Engel JB, Ludwig M, Felberbaum R et al. 2002 Use of cetrorelix in combination with clomiphene citrate and gonadotrophins: a suitable approach to 'friendly IVF'? Human Reproduction 17, 2022-2026.
20. European and Middle East Orgalutran Study Group 2001 Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stimulation. Human Reproduction 16, 644-651.
21. European Orgalutran® Study Group, Borm G, Mannaerts B 2000 Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomised, multicentre trial. Human Reproduction 15, 1490-1498.
22. Felberbaum RE 1999 Cetrorelix in controlled ovarian stimulation for ART: results of phase III, multiple dose treatment. Gynecology and Endocrinology 13 (suppl.), 114.
23. Felberbaum RE, Reissmann T, Küpker W et al. 1995 Preserved pituitary response under ovarian stimulation with HMG and GnRH antagonists (cetrorelix) in women with tubal infertility. European Journal of Obstetrics, Gynecology and Reproductive Biology 61, 151-155.
24. Felberbaum R, Reissmann T, Küpker W et al. 1996 Hormone profiles under controlled ovarian stimulation with human menopausal gonadotropin (HMG) and concomitant administration of the gonadotropin releasing hormone (GnRH)-antagonist cetrorelix at different dosages. Journal of Assisted Reproduction and Genetics 13, 216-222.
25. Felberbaum RE, Ludwig M, Diedrich K 1998 Are we on the verge of a new era in ART? Human Reproduction 13, 1778-1780.
26. Felberbaum RE, Albano C, Ludwig M et al. 2000 Controlled ovarian stimulation for assisted reproduction with HMG and concomitant midcycle administration of the GNRH-antagonist cetrorelix (Cetrotide®) according to the multiple dose protocol-results of a prospective non-controlled phase III study. Human Reproduction 15, 1015-1020.
27. Felberbaum R, Daya S, Fischer R et al. 2002 Cost-effectiveness modelling of recombinant FSH (r-hFSH) versus urinary FSH (u-hFSH) in assisted reproduction techniques in Germany. Geburtshilfe und Frauenheilkunde 62, 668-676.
28. Frydman R, Conel C, De Ziegler D et al. 1991 Prevention of premature luteinizing hormone and progesterone rise with a gonadotropin-releasing hormone antagonist, Nal-Glu, in controlled ovarian hyperstimulation. Fertility and Sterility 56, 923-927.
29. Ganirelix Dose-Finding Study Group 1998 A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon). Human Reproduction 13, 3023-3031.
30. Hardy RI, Tummon IS, Hosseinzadeh M et al. 2001 Luteinizing hormone (LH) surge in ganirelix (Antagon) is related to body mass index (BMI). Fertility and Sterility 3, 178-179.
31. Hernandez ER 2000 Embryo implantation: the Rubicon for GnRH antagonists. Human Reproduction 15, 1211-1216.
32. Howles C 2002 The place of gonadotrophin-releasing hormone antagonists in reproduction. Reproductive BioMedicine Online 4 (suppl. 3), 64-71.
33. Hsueh AJ, Jones PB 1981 Extrapituitary actions of gonadotropin-releasing hormone. Endocrine Reviews 2, 437-461.
34. Ikeda M, Taga M, Kurogi K, Minaguchi H 1997 Gene expression of gonadotropin-releasing hormone, but not its receptor, in human endometrium and decidua. Molecular and Cellular Endocrinology 135, 165-168.
35. Itskovitz-Eldor J, Kol S, Mannaerts B 2000 Use of a single bolus of GnRH agonist triptorelin to trigger ovulation after GnRH antagonist ganirelix treatment in women undergoing ovarian stimulation for assisted reproduction, with special reference to the prevention of ovarian hyperstimulation syndrome: preliminary report. Human Reproduction 15, 1965-1968.
36. Kol S, Lightman A, Hillensjö T et al. 1999 High doses of gonadotrophin-releasing hormone antagonist in in-vitro fertilization cycles do not adversely affect outcome of subsequent freeze-thaw cycles. Human Reproduction 14, 2242-2244.
37. Ludwig M, Albano C, Olivennes F et al. 2002 Plasma and follicular fluid concentration of LHRH antagonist cetrorelix (Cetrotide ®) in controlled ovarian stimulation for IVF. Archives of Gynecology and Obstetrics 266, 12-17.
38. Ludwig M, Bauer O, Diedrich K 1997a Überblick über das ovarielle Überstimulationssyndrom: ein reproduktionsmedizinisch-iatrogenes Krankheitsbild mit internistischer Konsequenz. Wien Medizinische Wochenschrifte 147, 516-524.
39. Ludwig M, Montzka P, Felberbaum R et al. 1997b Clomifenstimulation bei Zyklen zur intracytoplasmatischen Spermieninjektion (ICSI). Geburtshilfe und Frauenheilkunde 57, 561-565.
40. Ludwig M, Riethmüller-Wintzen H, Felberbaum R et al. 2001 Health of 227 children born after controlled ovarian stimulation for in vitro fertilization using the luteinizing horone-releasing hormone antagonist cetrorelix. Fertility and Sterility 75, 18-22.
41. Meltzer S, Girsh E, Shults A et al. 2002 Prevention of ovarian hyperstimulation syndrome in high responders undergoing IVF treatment with GnRH antagonist combined with single dose of GnRH agonist, instead of HCG, for the induction of oocyte maturation. Human Reproduction 17 (Abstract Book 1), 89 (abstr.).
42. North American Ganirelix Study Group, Fluker M, Grifo J, Leader A et al. 2001 Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation. Fertility and Sterility 75, 38-45.
43. Olivennes F, Fanchin R, Bouchard P et al. 1994 The single or dual administration of the gonadotrophin-releasing hormone antagonist cetrorelix in an in vitro fertilization-embryo transfer programme. Fertility and Sterility 62, 468-476.
44. Olivennes F, Fanchin R, Bouchard P et al. 1995 Scheduled administration of a gonadotrophin-releasing hormone antagonist (cetrorelix) on day 8 of in-vitro fertilization cycles: a pilot study. Human Reproduction 10, 1382-1386.
45. Olivennes F, Fanchin R, Bouchard P et al. 1996 Triggering of ovulation by a gonadotropin-releasing hormone (GnRH) agonist in patients pretreated with a GnRH antagonist. Fertility and Sterility 66, 151-153.
46. Olivennes F, Alvarez S, Bouchard P et al. 1998 The use of a GnRH antagonist (cetrorelix) in a single dose protocol in IVF-embryo transfer: a dose finding study of 3 versus 2 mg. Human Reproduction 13, 2411-2414.
47. Olivennes F, Belaisch-Allart J, Emperaire JC et al. 1999 Comparison in a prospective multicentric randomised study in IVF/ET of a single dose of GnRH antagonist (cetrorelix) to a GnRH agonist long protocol (triptorelin in depot formula). Gynecology and Endocrinology 13, 114.
48. Olivennes F, Belaisch-Allart J, Emperaire JC et al. 2000 Prospective, randomised, controlled study of in-vitro fertilization-embryo tranfer with a single dose of a luteinizing hormone-releasing hormone (LH-RH) antagonist (cetrorelix) or a depot formula of an LH-RH agonist (triptorelin). Fertility and Sterility 73, 314-320.
49. Olivennes F, Mannaerts B, Struijs M et al. 2001 Perinatal outcome of pregnancy after GnRH antagonist (ganirelix) treatment during ovarian stimulation for conventional IVF or ICSI: a preliminary report. Human Reproduction 16, 1588-1591.
50. Porter RN, Smith W, Craft IL et al. 1984 Induction of ovulation for in-vitro-fertilisation using buserelin and gonadotropins. Lancet 2, 1284-1285.
51. Raga F, Casan EM, Kruessel JS et al. 1998 Quantitative gonadotropin releasing hormone gene expression and immunohistochemical localization in human endometrium throughout the menstrual cycle. Biology of Reproduction 59, 661-669.
52. Reissmann T, Felberbaum R, Diedrich K 1995 Development and applications of luteinizing hormone-releasing hormone antagonists in the treatment of infertility: an overview. Human Reproduction 10, 1974-1981.
53. Ron-EL R, Herman A, Golan A et al. 1990 Follicle cyst formation following long acting gonadotropin-releasing hormone analog administration. Fertility and Sterility 52, 1063-1066.
54. Ron-El R, Herman A, Golan A et al. 1991 Gonadotropins and combined gonadotropin releasing hormone agonist-gonadotropins protocols in a randomised prospective study. Fertility and Sterility 55, 564-578.
55. Rongières-Bertrand C, Olivennes F, Righini C et al. 1999 Revival of the natural cycles in in-vitro fertilization with the use of a new gonadotropin-releasing hormone antagonist (cetrorelix); a pilot study with minimal stimulation. Human Reproduction 14, 683-688.
56. Rote Liste 2002 Arzneimittelverzeichnis für Deutschland. Rote Liste Service GmbH, Frankfurt/Main, Germany.
57. Silverberg K, Daya S, Auray JP et al. 2002a Analysis of the cost effectiveness of recombinant versus urinary follicle-stimulating hormone in in vitro fertilization/intracytoplasmic sperm injection programs in the United States. Fertility and Sterility 77, 107-113.
58. Silverberg K, Schertz J, Falk B, Beresniak A 2002b Impact of urinary FSH price: a cost-effectiveness analysis of recombinant and urinary FSH in assisted reproduction techniques in the USA. Reproductive BioMedicine Online 5, 265-269.
59. Smitz J, Ron-El R, Tarlatzis B 1992 The use of gonadotropin releasing hormone agonists for in vitro fertilization and other procreation techniques: experience from three centres. Human Reproduction 7, 49-66.
60. Stanger JD, Yovich JL 1985 Reduced in vitro fertilization of human oocytes from patients with raised basal luteinizing hormone levels during the follicular phase. British Journal of Obstetrics and Gynecology 92, 385-393.
61. Takeuchi S, Futamura N, Minoura H, Toyoda N 1998 Possible direct effect of gonadotropin releasing hormone on human endometrium and decidua. Life Science 62, 1187-1194.
62. Templeton A, Morris JK 1998 Reducing the risk of multiple birth by transfer of two embryos after IVF. New England Journal of Medicine 339, 573-577.
63. Weiss JM, Oltmanns K, Gurke EM et al. 2001 Actions of gonadotrophin-releasing hormone antagonists on steroidogenesis in human granulosa lutein cells. European Journal of Endocrinology 144, 677-685.